Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28650761 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DDB1CRBNMCL1MAPT | |
| SCHEMBL44224 | 0.92 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNMCL1MAPT | |
| SCHEMBL31220632 | 0.84 | ALDH1A1 (0.47) | ALDH1A1DDB1CRBNHTTKDM4E | |
| SCHEMBL6332550 | 0.84 | MCL1 (0.49) | ALDH1A1DDB1CRBNMCL1MAPT | |
| SCHEMBL9386437 | 0.82 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNKDM4EPKM | |
| SCHEMBL30431491 | 0.82 | ALDH1A1 (0.49) | ALDH1A1DDB1CRBNMCL1MAPT | |
| SCHEMBL5042931 | 0.82 | CES2 (0.41) | DDB1CRBNIDO1 | |
| SCHEMBL14331806 | 0.82 | CRBN (0.63) | ALDH1A1DDB1CRBNMCL1POLB | |
| SCHEMBL25263449 | 0.80 | ALDH1A1 (0.44) | ALDH1A1DDB1CRBNMAPTHTT | |
| SCHEMBL30462621 | 0.80 | MAPT (0.46) | ALDH1A1MCL1MAPTALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448965-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2012-05-09 | — | — | EP | claimed |
| WO-2011000095-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-01-06 | — | — | WO | claimed |
| US-12458705-B2 | Antibody-oligonucleotide conjugates | ANGIEX, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | ANGIEX, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250296957-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2025-09-25 | — | — | US | disclosed |
| EP-4619041-A1 | DRUG CONJUGATE COMPOUNDS FOR STIMULATING THE ANTITUMOR IMMUNE RESPONSE | THERATECHNOLOGIES INC. (CA) | 2025-09-24 | — | — | EP | disclosed |
| EP-3925969-B1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS SEC (CA) | 2025-09-03 | — | — | EP | disclosed |
| EP-3350333-B2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250186624-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ARES CAPITAL CORPORATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| US-20250152730-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | ANGIEX, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4536290-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | Angiex, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-0063017-A1 | Detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1982-10-20 | — | — | EP | disclosed |
| EP-0062523-A2 | Detergent additive compositions and preparations and use thereof in detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
| EP-0051987-A1 | Bleach activator compositions, preparation thereof and use in granular detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1982-05-19 | — | — | EP | disclosed |
| US-4321157-A | SILICA OR SILICATE, ORGANIC PEROXY ACID BLEACH PRECURSOR, ALIPHATIC ALCOHOL-ALKYLENE OXIDE CONDENSATE NONIONIC SURFACTANT | THE PROCTER & GAMBLE COMPANY (US) | 1982-03-23 | — | — | US | disclosed |
| EP-0034387-A2 | Mulls containing chain structure clay suspension aids | THE PROCTER & GAMBLE COMPANY (US) | 1981-08-26 | — | — | EP | disclosed |
| EP-0028432-A1 | Granular laundry compositions | THE PROCTER & GAMBLE COMPANY (US) | 1981-05-13 | — | — | EP | disclosed |
| US-4264466-A | LAUNDRY DETERGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1981-04-28 | — | — | US | disclosed |
| US-4248928-A | TETRAACETYL AKYLENEDIAMINES OR TETRAACETYL GLYCOURIL PEROXY BLEACH PRECURSOR | THE PROCTER & GAMBLE COMPANY (US) | 1981-02-03 | — | — | US | disclosed |
| US-4179390-A | Laundry additive product | THE PROCTER & GAMBLE COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | TM9SF4, TM9SF2, TM9SF3 | ALDH1A1 2725/4885DDB1 1008/4885CRBN 2679/4885 |
| US-20250296957-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | NGLY1, VIP, NPY1R | ALDH1A1 4790/4885DDB1 983/4885CRBN 793/4885 |
| US-20250186624-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | POLR2E, POLN, PHAX | ALDH1A1 4559/4885DDB1 181/4885CRBN 2700/4885 |
| US-12458705-B2 | Antibody-oligonucleotide conjugates | TM9SF4, TMSB4X, IGSF11 | ALDH1A1 4144/4885DDB1 747/4885CRBN 2271/4885 |
| US-20250152730-A1 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | TM9SF4, TM9SF2, TMPRSS4 | ALDH1A1 2608/4885DDB1 798/4885CRBN 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.